Jim O'Neill Optimistic His AMR Review Won't Run Into The Sand
This article was originally published in Scrip
Jim O'Neill says he spends sleepless nights worrying whether his Review of Antimicrobial Resistance (AMR) will run out of steam once completed in two months' time – but he's encouraged by growing evidence world leaders and the pharma industry are seriously embracing the theme and will soon make lasting commitments to effectively combat antibiotic resistance.
You may also be interested in...
The Nordic region’s vibrant life sciences ecosystem will be the chief focus for newly created Eir Ventures, a strategic partnership and investment company.
After talking with the FDA, Atox will file an NDA for its necrotizing soft tissue infections therapy despite missing primary endpoints in a pivotal trial, the biotech’s CEO tells Scrip.
Gesynta’s SEK190m ($20m) private placement allows its lead asset to enter Phase IIa studies for treating chronic inflammatory conditions in certain systemic sclerosis patients.